What You Should Know: - GoodRx today announced it is working with Sanofi, a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35. - This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. It leverages GoodRx’s reach
Read More
insulin
Expectations For The Connected Care Business In The Years Ahead
Though we seldom see their use in our modern world and, even then, only in fiction, there was a time when it was common for people to actually use things like crystal balls and divining rods to try to uncover unknown yet valuable information. As unbelievable as it may seem, soothsayers peered into crystal balls aiming to help seekers look into the future for guidance, while prospectors would rely earnestly on divining rods as they attempted to locate underground riches of water or oil. While
Read More
How AI Can Deliver Benefits in Healthcare Manufacturing and Patient Device Usage
According to Grand View Research, the global artificial intelligence (AI) in the healthcare market size was valued at USD 15.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.5% from 2023 to 2030, to reach an estimated USD 208.2 billion. That’s an impressive growth rate, indicating the expected value delivery to a mostly early-phase adoption of AI in the healthcare marketplace. With such aggressive predicted growth, many health industry professionals
Read More
Glytec Unveils Real-Time Analytics to Help Hospitals Prepare for New CMS Measures
What You Should Know: Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the next evolution of GlucoMetricsⓇ to provide new analytics, dashboards and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility this provides is essential as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia
Read More
Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients
What You Should Know: - Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance. The price cut goes into effect January 1, 2024. - The price cut milestone comes in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people
Read More
Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B
What You Should Know: - Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of approximately $2.9B. - The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet
Read More
Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month
What You Should Know: - Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month at participating retail pharmacies. - The historic price cut makes it easier to access Lily insulin for Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable
Read More
Dexcom Ventures Invests in MedCrypt’s Medical Device Cybersecurity Platform
What You Should Know: - MedCrypt, the proactive cybersecurity solution provider for medical devices and manufacturers, will announce the close of a Series B extension round led by Dexcom Ventures, bringing the company's total to date to $36.4M. - With support from three major investors, Johnson & Johnson Innovations, Intuitive Ventures, and Dexcom Ventures, MedCrypt continues to lead the way in developing cybersecurity technologies and infrastructure for life-saving medical
Read More
22 Executive Digital Health Predictions to Watch in 2023
Jon Bloom, MD, CEO and Co-founder of Podimetrics From a digital health perspective, 2022 was a reset year for many and a serious reality check. We went from sky high growth to the sky is falling, and in 2023 I think this market correction movement will continue forward. To me, the biggest surprise of 2022 was that despite the market tanking, digital health companies continued to truck forward with huge deals. This includes massive acquisitions like Amazon and OneMedical, as well as deals like
Read More
Prescryptive Health Taps Lilly on First-to-Market Value-Based Program to Stabilize Insulin Pricing
What You Should Know: - Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market partners with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. - Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs.
Read More
